Indications
For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.
Composition
- Active substance
- spironolactone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Spironolactone Ceva
- Active substance
- spironolactone
- Group
- Veterinary medicines
- Marketing authorisation holder
- Ceva Santé Animale
- Status
- Withdrawn
- EU authorisation
- 20 Jun 2007
- EMA product number
- EMEA/V/C/000105